Malignant lymphoma of the conjunctiva following Hodgkin’s disease

HANS E GROSSNIKLAUS, DIANE C FARHI, BRUCE R JACOBSON, AND MARY FAITH ABBUHL

From the Division of Ophthalmology and Institute of Pathology, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, USA

SUMMARY A 64-year-old woman with mixed cellularity Hodgkin’s disease diagnosed in 1972 developed a malignant lymphoma of the conjunctiva 14 years later. She had undergone combined chemotherapy and radiation therapy for Hodgkin’s disease. Non-Hodgkin’s lymphomas developing after Hodgkin’s disease have been reported with increasing frequency in recent years. It is important to recognise a separate malignant lymphoma in a patient with Hodgkin’s disease because of the different treatment offered for each of these diseases.

Hodgkin’s disease rarely involves the conjunctiva. However, non-Hodgkin’s lymphoma of the conjunctiva is not uncommon. There have been several reports in recent years describing patients with Hodgkin’s disease who later developed a separate non-Hodgkin’s lymphoma. There has been some suggestion that the separate lymphoma may be related to chemotherapy or radiation therapy for the Hodgkin’s disease. It is also possible that newer diagnostic techniques permit the diagnosis of non-Hodgkin’s lymphoma in lesions previously interpreted as Hodgkin’s disease.

We report the clinical and histopathological findings in a 64-year-old woman with treated Hodgkin’s disease who presented with a conjunctival malignant lymphoma. Immunohistochemical analysis and cell flow cytometry were used to characterise the conjunctival lymphoma.

Case report

A 64-year-old white woman was examined for irritation of her right eye which had been present for approximately one week. Examination showed her best corrected visual acuity to be 20/20 in each eye. Pupillary and ocular motility testing were normal. External examination was remarkable for an 8×8 mm salmon-coloured subconjunctival mass in the area of the plica semilunaris with extension into the inferior fornix of her right eye (Fig. 1). The rest of the external, tonographic, and funduscopic examinations were normal. A physical examination and chest x-ray showed no lymphadenopathy. An excisional biopsy of the subconjunctival mass was performed (description below).

The patient’s past medical history was significant for Hodgkin’s disease diagnosed 14 years previously. The Hodgkin’s disease was diagnosed by hilar and right scalene lymph node biopsies performed in 1972 after a chest x-ray showed a mediastinal mass (Fig. 2) and physical examination showed an enlarged right scalene lymph node. Staging procedures including bone marrow biopsies, splenectomy, and liver biopsy

Fig. 1 Appearance of right eye with medial, salmon-coloured conjunctival mass (arrowhead).
Malignant lymphoma of the conjunctiva following Hodgkin’s disease

failed to show tumour. She was considered to have Hodgkin’s disease, stage IIB. Radiation therapy totalling 4400 rads was administered to her upper mantle. She did well until 1973, when she developed a left pleural effusion. A thoracentesis of the left pleural space showed lymphocytes, neutrophils, and mesothelial cells. She was given six courses of chemotherapy including carmustine vinblastine, and cyclophosphamide, the last treatment being administered on 10 April 1974.

Four subsequent treatments of MOPP (nitrogen mustard, Oncovin (vincristine, prednisone, and procarbazine) were given, the last on 12 July 1974. The patient developed disseminated herpes zoster on 27 July 1974, which resolved after systemic treatment with cytarabine. She received no further radiation or chemotherapy for her Hodgkin’s disease. Bone marrow biopsies and a liver biopsy were negative for tumour in 1975, and her course was unremarkable until the development of her conjunctival lesion in 1986.

**Pathological findings**
Examination of the cervical and hilar lymph nodes excised in 1972 showed fragments of lymph node surrounded by loose connective tissue. Nearly the entire nodal architecture was effaced by an infiltrate of histiocytes, lymphocytes, eosinophils, and plasma cells in which were scattered numerous diagnostic Reed-Sternberg cells and abundant mononuclear and multilobulated Reed-Sternberg variants (Fig. 3). Rare lacunar cells were present, but there was no evidence of lamellar fibrosis. The Reed-Sternberg cells and variants were strongly positive for Leu-M1. The findings were diagnostic of Hodgkin’s disease, mixed cell type.

The conjunctival specimen consisted of mucosa and underlying soft tissue, infiltrated by a dense population of small cleaved and large cleaved and non-cleaved lymphocytes (Figs. 4A, B). Admixed were numerous small, round lymphocytes with compact chromatin. There was no evidence of follicle formation; plasmacytoid features were not seen. No Reed-Sternberg cells were present. A portion of the fresh tissue was submitted for cell surface marker studies by flow cytometry, yielding the following results: anti-surface immunoglobulin (SIg) 72%, anti-kappa 39%, anti-lambda 35%, anti-OKIa-l 77%, anti-OKT1 28%, anti-OKT3 22%, anti-cALLa 25%, and anti-TAC 6%. The finding of 28% mature T cells (OKT1 and OKT3 positive) indicated a significant admixture of reactive lymphocytes. The results were most compatible with a population of lambda-bearing neoplastic cells (approximately 25%) admixed with reactive B and T cells. The presence of benign, reactive lymphocytes was often seen in malignant lymphoma, as in other neoplasms, and in this case represented a significant proportion of the cells separated from the tissue prior to flow cytometry. The recovery of relatively low numbers of neoplastic SIg-bearing cells has been previously noted. This interpretation was further supported by immunocytochemical studies done on frozen sections, showing numerous small, round lympho-
cells

Conjunctival

Fig. 4A  Conjunctiva with mixed population of small and large lymphoid cells with prominent nuclear irregularities. Haematoxylin and eosin.

eytes staining as T cells (Leu 1, Leu 5 positive), the majority having a helper T cell phenotype (Leu 3) and a minority suppressor T cell phenotype (OKT 8). These constituted about 25% of the cells seen, in accordance with the flow cytometry results. Immuno-

cytocchemical studies on frozen and B5-fixed paraffin-embedded tissue showed staining of abnormal, large lymphoid cells for lambda and IgG in approximately 5% of cells; in rare large lymphoid cells staining for IgM was noted.

Discussion

It is not usual for a second malignant neoplasm to develop in patients with Hodgkin’s disease. The most common second malignancy is acute myelo-

blastic leukaemia. Non-Hodgkin’s lymphomas have been reported to occur as a second malignancy with an estimated frequency of 0.9% to 2.1%. Jacques et al. reviewed the literature and found that approximately 50% of the reported cases of non-

Hodgkin’s lymphoma in patients with previous Hodgkin’s disease involved the digestive tract. Seventeen of the 24 patients they reviewed had previous chemotherapy plus radiation therapy for their Hodgkin’s disease (as in our case), three had chemotherapy, and three had radiation therapy alone. The lymphomas in previous cases have included nodular and diffuse patterns, composed of B and T cells, including immuno-

blastic and Burkitt’s lymphoma. Sigelman and Jakobiec included a patient with malignant lymphoma of mixed cell type of the conjunctiva with a history of Hodgkin’s disease in their review of 40 patients with lymphoid lesions of the conjunctiva. The authors questioned the original diagnosis of Hodgkin’s disease, since the slides from the original biopsy could not be located and the original diagno-

sis of Hodgkin’s disease was made from a biopsy of the tonsillar region, an extremely rare site for involvement by Hodgkin’s disease. The interval between the diagnosis of Hodgkin’s disease and conjunctival lymphoma was not reported.

It is well known that Hodgkin’s disease may progress to a histopathological subtype with a less favourable prognosis; transformation to non-

Hodgkin’s lymphoma is believed not to occur. It is possible for both non-Hodgkin’s lymphoma and Hodgkin’s disease to occur concurrently in a rare condition termed ‘composite lymphoma’. In our case 14 years elapsed between the original diagnosis and the appearance of the conjunctival lymphoma, precluding the possibility of composite lymphoma.

The phenomenon of a second lymphoma occurring in patients with Hodgkin’s disease appears to have been recognised only recently. Two explanations for these recent observations are proposed. It is possible that with newer diagnostic techniques, including immunohistochemical analysis for T and B cells, malignant lymphomas are recognised which may previously have been mistaken for Hodgkin’s disease. Alternatively, chemotherapy and radiation therapy may predispose patients with Hodgkin’s disease to a second lymphoproliferative disorder. Patients with Hodgkin’s disease may have defects in their immune surveillance system which predisposes them to second malignancies. A combination of these explanations may be a factor in the relatively recent descriptions.

It is important for the ophthalmologist and the pathologist to recognise the possibility of non-

Hodgkin’s lymphoma occurring in the conjunctiva of patients with previous Hodgkin’s disease, as these malignancies require different treatment.
Malignant lymphoma of the conjunctiva following Hodgkin’s disease

References


Accepted for publication 20 January 1987.
Malignant lymphoma of the conjunctiva following Hodgkin's disease.
H E Grossniklaus, D C Farhi, B R Jacobson and M F Abbuhl

doi: 10.1136/bjo.72.3.212

Updated information and services can be found at:
http://bjo.bmj.com/content/72/3/212

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/